Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amerifit's Estroven

This article was originally published in The Tan Sheet

Executive Summary

Being supported with 10-second TV tags, print, syndicated talk radio, direct-mail coupons and free-standing inserts. Bloomfield, Conn.-based Amerifit began shipping the 30-count soy isoflavone/black cohosh/vitamin E product for menopausal symptoms to health food stores, drug chains and mass marketers in December; Estroven is now on shelves at retailers including Wal-Mart, Target, CVS and Eckerd. The product, with prices varying depending on the retail channel, claims to be "the natural way to maintain a women's balance." Bozell Worldwide, New York City, is handling the creatives for the account. The ad budget for the product's 90-day introduction is $3 mil. Last summer, the company had discussed introducing a similar product, Estrust, into the market. Based on feedback from retailers at the 1997 National Association of Chain Drug Stores Marketplace conference, the product was never rolled out; after changing the formula (black cohosh and kava kava have been added and dong quai and chaste berry removed, among other alterations) and revising marketing plans, the product has become Estroven ("The Tan Sheet" July 7, 1997, p. 15)...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel